person · Reporting owner

OGILVIE SCOTT VARDE

Disclosed activity across 2 companies

Tapewire entity: 154473
SEC CIK: 0001379413

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Inspyr Therapeutics, Inc.NSPX · Entity 173805	Director	March 03, 2017	March 06, 2017
PALISADE BIO, INC.CUR · Entity 5803	Director	July 01, 2019	October 11, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inspyr Therapeutics, Inc.

Report date March 03, 2017 · Filed March 06, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock purchase optionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2022-03-03	Direct	2,335	Reported balance After 2017-03-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-03-03 · Grant · Acquired 2,335 · Balance 2,335 F1: Represents compensatory Annual Grant and Committee Grants for director services. The options vest quarterly on 6/3/17, 9/3/17, 12/3/17, and 3/3/18.

Filing footnotes · ownership attribution and instrument terms

F1: Represents compensatory Annual Grant and Committee Grants for director services. The options vest quarterly on 6/3/17, 9/3/17, 12/3/17, and 3/3/18.

PALISADE BIO, INC.

Report date July 01, 2019 · Filed October 11, 2019 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock Purchase OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2029-07-01	Direct	10,106	Reported balance After 2019-07-01 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2019-07-01 · Grant · Acquired 10,106 · Balance 10,106 F1: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. F3: This amendment is being filed to correct a scrivener's error with regard to the option amount previously reported. F2: All exercise prices and share amounts reported in this Form 4/A reflect a 1-for-20 reverse split that occurred on July 17, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20.

F2: All exercise prices and share amounts reported in this Form 4/A reflect a 1-for-20 reverse split that occurred on July 17, 2019.

F3: This amendment is being filed to correct a scrivener's error with regard to the option amount previously reported.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 01, 2019 Filed Jul 3, 2019 21:35 UTC	PALISADE BIO, INC. CUR · Entity 5803	GrantCommon Stock Purchase Option · Derivative	187,510	$0.00 Strike: $0.30	$0.00	Disclosure SEC source: 0001171843-19-004417 · ownership.xml · derivative · entry 1 OGILVIE SCOTT VARDE · CIK 0001379413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,510 Underlying: Common Stock · 187,510 shares Expires 2029-07-01 F1 · security: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. F1 · derivative.exercise_date: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. Read SEC document
July 01, 2019 Filed Oct 11, 2019 23:23 UTC Amendment	PALISADE BIO, INC. CUR · Entity 5803	GrantCommon Stock Purchase Option · Derivative	10,106	$0.00 Strike: $6.00	$0.00	Disclosure SEC source: 0001171843-19-006480 · ownership.xml · derivative · entry 1 OGILVIE SCOTT VARDE · CIK 0001379413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,106 Underlying: Common Stock · 10,106 shares Expires 2029-07-01 F1 · security: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. F3 · security: This amendment is being filed to correct a scrivener's error with regard to the option amount previously reported. F2 · derivative.exercise_price: All exercise prices and share amounts reported in this Form 4/A reflect a 1-for-20 reverse split that occurred on July 17, 2019. F2 · shares: All exercise prices and share amounts reported in this Form 4/A reflect a 1-for-20 reverse split that occurred on July 17, 2019. F3 · shares: This amendment is being filed to correct a scrivener's error with regard to the option amount previously reported. F1 · derivative.exercise_date: Represents 50% of compensatory Annual Grant for director services equal to $50,000. The options vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/20. Read SEC document
July 02, 2018 Filed Jul 5, 2018 20:32 UTC	PALISADE BIO, INC. CUR · Entity 5803	GrantCommon Stock Purchase Option · Derivative	59,660	$0.00 Strike: $1.11	$0.00	Disclosure SEC source: 0001171843-18-005065 · formfour.xml · derivative · entry 1 OGILVIE SCOTT VARDE · CIK 0001379413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,660 Underlying: Common Stock · 59,660 shares Expires 2028-07-02 F1 · security: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/18, 12/31/18, 3/31/19, and 6/30/19. F1 · derivative.exercise_date: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/18, 12/31/18, 3/31/19, and 6/30/19. Read SEC document
July 14, 2017 Filed Jul 18, 2017 20:30 UTC	PALISADE BIO, INC. CUR · Entity 5803	GrantCommon Stock Purchase Option · Derivative	13,574	$0.00 Strike: $5.37	$0.00	Disclosure SEC source: 0001171843-17-004168 · formfour.xml · derivative · entry 1 OGILVIE SCOTT VARDE · CIK 0001379413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,574 Underlying: Common Stock · 13,574 shares Expires 2027-07-14 F1 · security: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/17, 12/31/17, 3/31/18, and 6/30/18. F1 · derivative.exercise_date: Represents 50% of compensatory Annual Grant for director services of $100,000. The options vest quarterly on 9/30/17, 12/31/17, 3/31/18, and 6/30/18. Read SEC document
March 03, 2017 Filed Mar 6, 2017 17:18 UTC	Inspyr Therapeutics, Inc. NSPX · Entity 173805	GrantCommon Stock purchase option · Derivative	2,335	$0.00 Strike: $0.54	$0.00	Disclosure SEC source: 0001144204-17-013011 · v461239_form4.xml · derivative · entry 1 OGILVIE SCOTT VARDE · CIK 0001379413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,335 Underlying: Common Stock · 2,335 shares Expires 2022-03-03 F1 · security: Represents compensatory Annual Grant and Committee Grants for director services. The options vest quarterly on 6/3/17, 9/3/17, 12/3/17, and 3/3/18. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.